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Abstract
Pseudohypoparathyroidism refers to a heterogeneous group of disorders characterized by
parathyroid hormone (PTH) resistance. Pseudohypoparathyroidism is an uncommon sporadic or
inherited genetic disorder subdivided into several distinct entities (type Ia, Ib, Ic, type II). We report
cases of four children (aged 8 to 13 years) in the winter season 2007-’08. The present work highlights
the variable mode of presentation of pseudohypoparathyroidism and the difficulty of an early
diagnosis. We stress the importance of a complete biochemical investigation of the calcium-
phosphate metabolism to recognize typical biochemical alterations associated with this condition
(hypocalcaemia, hyperphosphataemia with increased phosphate tubular reabsorption and elevated
PTH levels) in spite of a phenotypic aspect that often lacks the presence of all the peculiar clinical
features of Albright hereditary osteodistrophy.
Introduction
Pseudohypoparathyroidism (PHP) refers to a heteroge-
neous group of disorders characterized by parathyroid
hormone (PTH) resistance. PHP is an uncommon
sporadic or inherited genetic disorder subdivided into
several distinct entities.
In the past the diagnosis of PHP was confirmed by the
administration of bovine or synthetic PTH. This test
helped to distinguish patients with PHP type I (character-
ized by a reduced urinary cAMP and phosphate excretion)
from patients with PHP type II (characterized by a normal
urinary cAMP excretion and a reduced phosphate
excretion). PHP type I is generally classified by subtypes
Ia, Ib and Ic, according to different phenotypes, genetic
findings and pathogenesis. All subtypes are caused by
mutation or imprinting abnormalities in the stimulatory G
protein (Gs). The alpha-subunit of the Gs(Gsa) is a
signalling protein essential for the actions of PTH and
many other hormones.
Type Ia PHP is characterized by resistance to PTH and other
hormones that stimulate adenyl cyclase in their target
tissues, such as thyroid stimulating hormone (TSH),
gonadotropins and growth hormone releasing hormone
(GHRH). This hormonal resistance leads to hypocalcaemia,
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hyperphosphataemia, elevated PTH levels, thyroid and
gonadal dysfunction. In addition, type Ia PHP is associated
with a constellation of peculiar clinical features collectively
termed Albright hereditary osteodystrophy (AHO). These
features include short stature, rounded face, brachydactyly,
brachymetacarpia, centripetal obesity, subcutaneous ossifi-
cations, and in some cases, mental or developmental delay.
Patients with type Ia PHP show only about 50% activity of
Gsa subunit. [1-5]
Type Ib PHP is characterized by resistance to PTH mainly
in the renal tissue and in a few others tissues such as the
thyroid, but without features of AHO [6-8].
Type Ic PHP is the rarest subtype and it is characterized by
AHO, resistance to PTH and other hormones in face of
normal Gsa activity.
Patients with PHP type II have hypocalcaemia, hyperpho-
sphataemia and increased serum PTH, but they lack the
physical features associated with AHO [9,10].
Pseudohypoparathyroidism is a rare disease and its
prevalence in diverse populations is currently unknown.
There are only two studies that reported epidemiologic
data on pseudohypoparathyroidism: a nation-wide survey
carried out in Japan reported a total of 220 cases of PHP
between 1968-1977 [11]. More recently another Japanese
study reported a prevalence of 3.4 per million population
[12].
The aim of our report was to describe the diversity of the
clinical presentation and disease course in four children




This case describes a Caucasian 13-year-old boy who
presented motor difficulties from birth. He came to
our attention after an episode of hypertonia, fixed
gaze lasting 1-2 minutes and loss of consciousness.
Biochemical analysis, performed during hospitalization
in the nearest hospital, showed low calcium concentration
(1.1 mmol/l = 4.4 mg/dl) for which he was treated with
calcium gluconate 10% ev. He also had elevated PTH
concentration (177 pg/ml, reference value 17-73) and
hyperphosphataemia (3.16-3.26 mmol/l = 9.5-9.8 mg/dl).
The ECG showed a long Q-T interval.
On his admission to our paediatric unit he was in a good
general condition, alert and collaborating, orientated in
space and time. He did not show signs of tetany. Clinically
he appeared tall, with tapering fingers, with neither teeth
diastasis nor enamel alterations. He showed mild
dysmorphic facial traits, bull neck, kyphosys, barrel-
shaped thorax, pseudogynecomasty, but neither rounded
face nor brachydactyly, or brachymetacarpia. The bio-
chemical analyses confirmed the hypocalcaemia, hyper-
phosphataemia and the elevated concentration of PTH
with low-normal vitamin D metabolites serum concentra-
tion (25OHD: 17.1 ng/ml, reference value 10-68;
1,25(OH)2D: 25.1 pg/ml, reference value 15-50) and
renal function. There were no other endocrine defects
(IGF-I, gonadotropin, testosterone, prolactin, cortisol,
adrenocorticotropic hormone were all within the reference
range). During hospitalization the calcium gluconate
infusion was continued and then converted to oral
calcium carbonate (2 g/day) associated with oral calcitriol
(1.25 mcg/day).
During the following months several therapeutic adjust-
ments were needed to maintain an adequate calcium-
phosphate balance. Currently the patient has achieved a
satisfactory calcium-phosphate homeostasis with 1.5 mcg/
day of calcitriol.
Patient 2
A Caucasian 10-year-old boy initially came to our
attention for rapidly progressing early puberty. After
clinical examination and biochemical hormonal analysis
the diagnosis was compatible with a heterozygous deficit
of 21-hydroxylase.
Six months later he presented an episode of tonic-clonic
seizures associated with loss of consciousness, overflow of
saliva, fixed gaze to the right, resolved spontaneously after
few seconds. For this reason a computed tomography (CT)
scan and a Magnetic Resonance Imaging (MRI) scan of the
brain were performed together with an Electroencephalo-
gram (EEG) (basal and after sleep deprivation): all these
investigations were normal.
At the age of 11 he referred to the emergency room of our
hospital with a lipothymic episode that occurred while
playing. Several biochemical examinations were per-
formed: a severe hypocalcaemia (1.75 mmol/l = 7 mg/dl)
was detected. Considering the previous convulsive
episodes, the boy was hospitalized for further analyses.
The calcium-phosphate metabolism revealed a low-nor-
mal calcium serum concentration (calcium 2.05 mmol/l =
8.2 mg/dl) and a phosphataemia at the upper normal
limits (2.14 mmol/l = 6.42 mg/dl) with a moderately
elevated PTH (77 pg/ml, reference value: 17.3-72.9). The
thyroid ultrasound scan was normal. At the clinical
examination the patient showed a brachymetacarpia of
the fourth finger in both hands (this trait was shared by his
mother and his grandfather). He did not have any other
dysmorphic trait. He began an oral therapy with calcium
carbonate (0.5 g/day) and calcitriol (0.25 mcg/day).
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A month later his calcium-phosphate metabolism was
partially normalized with a phosphataemia still at the
upper limits (2.3 mmol/l = 7 mg/dl). In the following
months the phosphataemia progressively lowered to the
normal values and the patient did not present other
convulsive episodes.
Patient 3
A Caucasian 12-year-old boy came to our attention with a
history of two syncopal episodes. The first one had
occurred four months before while cycling (the physical
stress was associated with an emotional stress because of
the bursting of a firecracker). During the following
hospitalization the electrocardiogram (ECG) showed a
long Q-T interval and the biochemical analyses revealed a
mild hypocalcaemia. The echocardiogram and all the
ergometric tests were normal. He began a therapy with
Nadolol 40 mg/day and the molecular analyses for the
long QT syndrome (LQTS) were performed. The cerebral
CT scan and the neurological examination were normal.
The EEG showed minimal non specific dysfunctional
notes.
Persistent hypocalcaemia (2.1 mmol/l = 8.4 mg/dl) with
high phosphate serum concentration (2.6mmol/l = 7.8mg/
dl) was still present a month later.
A second syncopal episode occurred. This time it was
preceded by dizziness and coincided with head rotation
to the left and hand twitch contractions. During hospita-
lization the biochemical analyses showed alterations
typical of pseudohypoparathyroidism: hypocalcaemia
(1.9 mmol/l = 7.6 mg/dl), hyperphosphataemia
(3.16 mmol/l = 9.5 mg/dl) and elevated PTH levels
(1157 pg/ml, reference values 12-72). The EEG confirmed
the non specific disfunction pathway. He started an
oral calcium supplementation with calcium carbonate
1 g/day.
This patient finally came to our Institute after a month of
calcium treatment. At the clinical examination, signs of
latent tetany (Trousseau and Chvostek signs) were present
and he had a mild kyphosis attitude. The boy did not
show the peculiar clinical features of Albright hereditary
osteodistrophy. He began a therapy with calcitriol 0.25 mcg
twice a day and calcium carbonate (1 g/day divided in four
doses). Ten days later the calcium was slightly higher
while the phosphate value did not change. With several
therapeutic adjustments the phosphataemia progressively
normalized in the following three months and the latest
biochemical analyses, performed 6 months after the
beginning of the combined therapy (Calcitriol + Calcium
Carbonate), showed a normal calcium, a slightly high
phosphate, but reduced if compared to the previous value,
and a PTH that decreased from 1088 to 162 pg/ml.
Patient 4
A Caucasian 8-year-old girl came to our outpatient clinics
presenting as markedly overweight and with the presence
of premature thelarche. Her height was 121.2 cm (3rd-10th
centile) and her weight 39 kg (>90th centile) with a BMI of
26.7 (>97th centile). She had stretch marks at her hips,
acanthosis nigricans on her neck and chest and cellulite.
The mammary glands had a diameter of approximately
1 cm. This precocious puberty associated with skeletal
abnormalities (she had a marked hypoplasia of the third,
fourth and fifth metacarpals shortening and a dysmorphia
of the carpal nucleus with a reduced carpal space) found
in a radiograph of the left hand and wrist had raised
the suspicion of an Albright hereditary osteodistrophy.
Several biochemical examinations were performed: all
results were within the normal range, except for an
elevated PTH (127 pg/ml, reference value 17.3-72.9).
The calcium phosphate metabolism, the phenotypic
aspect (rounded face, short stature, bull neck, squat
hands and feet, epicanthus) and the brachymetacarpia
strengthened the diagnostic hypothesis of an Albright
hereditary osteodistrophy. For this reason a genetic
analysis was planned (still in course).
During the following months she repeated the biochem-
ical analyses, which confirmed normal calcium and
phosphate levels, normal 25OHvitamin D and elevated
PTH. Two tests (arginine and dexamethasone) were
compatible with a growth hormone deficit. The phosphate
renal transport (TRP) and the phosphate maximum
transport (TmPO4) were elevated.
Table 1 summarizes the biochemical values showed by the
four patients at arrival to our Clinic.
Discussion
PHP is a complex disorder with extreme individual
variability. The diagnosis of this rare condition is often
delayed, leading to an initially inappropriate approach and
therapy. The present work highlights the variable mode of
presentation of PHP and the difficulty of an early diagnosis.
In our patients the typical biochemical alterations did
not appear in the first years of life, but after the tenth
Table 1. Biochemical values at the arrival to our observation
Refererence Value Patient 1 Patient 2 Patient 3 Patient 4
Calcium
2.2-2.7 (mmol/l) 1.26 2.18 1.72 2.32
8.8-10.8 (mg/dl) 5.04 8.72 6.9 9.28
Phosphate
0.95-1.75 (mmol/l) 2.68 2.14 3.0 1.6
2.85-5.25 (mg/dl) 8.04 6.42 9.0 4.8
PTH
17.3-72.9 (pg/ml) 219 77 1029 127
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year [2]. Although the initial clinical onset may be
related to a severe hypocalcaemia leading to seizures
or syncopal episodes, hypocalcaemic condition may
become clinically evident only during the pubertal
growth spurt, when the calcium requirements are higher.
Another important factor to be considered is the
seasonal period. It is usually during autumn or winter,
when the sun exposure is lower, that the 25OHvitamin
D reaches the lowest blood concentration that might
lead to hypocalcaemia.
The primary aim of this report is to stress the pivotal role of
a complete biochemical investigation of the calcium-
phosphate metabolism in every child presenting symptoms
suggestive of hypocalcaemia. It is extremely important to
perform a complete biochemical analysis (that always
includes calcium, phosphate, magnesium and parathyroid
hormone serum measurements) in order to distinguish
PHP from other disorders. For example, patient 3, after
syncopal episodes, performed biochemical analyses that
included serum calcium, but not phosphate or PTH, thus
preventing a prompt and correct diagnosis. It was only
during the second hospitalization that a complete bio-
chemical analysis was made, showing the typical alterations
of PHP.
The diagnosis is made more difficult by the various
phenotypic aspects correlated with PHP. PHP type Ia and
Ic are usually associated with a constellation of peculiar
clinical features collectively termed Albright hereditary
osteodistrophy (AHO). But the presence of all these
phenotypic aspects is rare, and two of our patients (patient
2 and 4) showed only a characteristic brachymetacarpia
without any other sign. In contrast, patient 1 did not
present any of the typical clinical features of AHO, even if
he had some peculiar phenotypic traits (mild dysmorphic
facial traits, tallness, tapering fingers, pseudogynecomasty,
kyphosys, bull neck, barrel-shaped thorax).
The diagnosis of PHP is nowadays based on clinical and
biochemical findings (hypocalcaemia, hyperphosphate-
mia with increased phosphate tubular reabsorption and
elevated PTH levels in subjects having a normal renal
function). Molecular characterization is currently a reliable
method to differentiate the various subtypes of PHP.
Table 2 summarizes the differences between PHPI sub-
types. The two main subtypes of PHP, PHP types Ia and Ib,
are caused by mutations of GNAS1, a gene encoding the
alpha subunit of the G stimulatory protein, coupled to the
PTH receptor. These gene mutations result in the G
protein’s inability to activate adenyl cyclase upon the
binding of PTH to its receptor. Activation of adenyl cyclase
is required for signal transduction that produces the end-
organ response to PTH. Failure of signal transduction
results in the unresponsiveness of the end organ [8].
GNAS1 is imprinted in humans so that expression of the
allele for a specific tissue is dependent on whether the
allele is maternally or paternally inherited. Thus, maternal
or paternal transmission leads to different disease mani-
festations. Heterozygous loss of function mutations in the
Gsa gene inherited from the mother lead to PHP Ia,
whereas the samemutation inherited from the father leads
to pseudoPHP, a distinct entity characterized by AHO,
without evidence of hormone resistance. In the thyroid,
gonads and pituitary glands, Gsa transcription mainly
derives from the maternal allele, thus explaining why only
patients with maternally inherited mutations (PHP Ia)
show resistance to various other G-protein coupled
hormones including TSH, gonadotropins and GHRH [4].
Patients with PHP Ib do not show AHO, and hormone
resistance appears to be limited to the renal actions of PTH
and occasionally TSH [6,8]. PHP Ib is transmitted only
from the mother. There are two variants of PHP type Ib: a
familial autosomal dominant form (AD-PHP Ib) and a
sporadic form. The proposed mechanism of both forms is
the disruption of long-range imprinting control elements
of GNAS1 locus, with consequent decreased Gsa tran-
scription in the proximal renal tubules and PTH resistance
[8]. Normally a renal tissue-specific repressor binds to a
negative regulatory element on exon 1A and suppresses Gs
expression on the paternal allele, but is unable to bind the
maternal allele due to methylation, allowing Gsa to be
expressed from the maternal allele. In PHP Ib, the
methylation of this exon is absent in the maternal allele,
allowing the repressor to link to both alleles and suppress
the Gsa expression [13].
The aim of PHP therapy is to obtain an adequate calcium-
phosphate control and to correct the multiple hormonal
resistance, when present. Treatment includes the use of
vitamin D active metabolites (alfacalcidol and calcitriol,
20-50 ng/kg/day given in two doses) and calcium
supplementation (intravenous calcium to correct sympto-
matic hypocalcaemia and then oral calcium administra-
tion according to individual response and dietary calcium
intake). The goal is to maintain blood calcium between
2.2-2.7 mmol/l (= 8.8-10.8 mg/dl), urinary calcium
excretion <4 mg/kg/day, and the urinary calcium/urinary
creatinine ratio <0.2. For this reason we recommend that
all patients undergo a biochemical (calcium, phosphorus,
Table 2. PHP I subtypes can be distinguished by phenotypic traits (AHO*),





PHPIa Yes Multiple #103580
PHPIb No Only to PTH #603233
PHPIc Yes Multiple #103580
*AHO: Albright hereditary osteodystrophy.
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PTH, creatinine) and urinary (calcium and creatinine)
examination every three months. A strict follow up is
essential to adjust the therapeutic dosage and to preserve a
difficult biochemical balance.
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